Cargando…
P1313: LOW DOSE RITUXIMAB FOR PRE-EMPTIVE TREATMENT OF EPSTEIN BARR VIRUS REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE-CENTER STUDY
Autores principales: | Mei, Chen, Ren, Yanling, Qian, Jiejin, Tong, Hongyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430505/ http://dx.doi.org/10.1097/01.HS9.0000972140.02638.3e |
Ejemplares similares
-
Pre-Emptive Use of Rituximab in Epstein–Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes
por: Papalexandri, Apostolia, et al.
Publicado: (2023) -
1601. Effect of Preemptive Rituximab Therapy on Epstein–Barr Reactivation in Allogenic Hematopoietic Stem Cell Pediatric Transplants
por: Catho, Gaud, et al.
Publicado: (2018) -
Pre-emptive Allogeneic Hematopoietic Stem Cell Transplantation in Ataxia Telangiectasia
por: Bakhtiar, Shahrzad, et al.
Publicado: (2018) -
Characteristics of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation in patients with chronic active Epstein–Barr virus disease: favorable responses to rituximab
por: Wei, Na, et al.
Publicado: (2021) -
Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation
por: Wu, Xiu-li, et al.
Publicado: (2012)